Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria

• •1. Adults aged 19 to 80 years.
• •2. Patients with Type 2 diabetes who are scheduled to receive initial treatment with Enavogliflozin or Enavogliflozin Extended-Release Tablets based on the attending physician's medical judgment, within the following insurance coverage ranges:
• •* Enavogliflozin monotherapy
• •* Combination therapy of Enavogliflozin with two agents (metformin)
• •* Combination therapy of Enavogliflozin with three agents (metformin + DPP-4 inhibitor)
• •3. Patients with obesity beyond the pre-obesity stage according to the 2022 Korean Endocrine Society obesity treatment guidelines:
• •* Pre-obesity stage: BMI 23\~24.9 kg/m2
• •* Stage 1 obesity: BMI 25\~29.9 kg/m2
• •* Stage 2 obesity: BMI 30\~34.9 kg/m2
• •* Stage 3 obesity: BMI ≥ 35 kg/m2
• •4. Individuals planning to undertake appropriate exercise and dietary therapy for glycemic control during the observational study period.
• •5. Fertile women and men who agree to contraception according to appropriate contraceptive methods during the observational study period or have no plans for pregnancy, adhering to methods such as hormonal contraceptives, intrauterine devices or systems, tubal ligation, vasectomy, dual contraception methods (such as cervical cap and male condom), etc.
• •6. Individuals who have received detailed explanation and have understood the nature of the observational study and the investigational drug, and have provided written consent to participate voluntarily in the observational study and to comply with subject precautions during the study period.